BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
BeyondSpring Inc. announced new preclinical data demonstrating that Plinabulin significantly improves both the anticancer efficacy and safety profile of leading antibody-drug conjugate (ADC) therapies. Presented at AACR 2026, the data show enhanced tumor response rates, longer survival, and reduced toxicities when Plinabulin is combined with ADCs w…